+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Depression Treatment Market

  • PDF Icon

    Report

  • 443 Pages
  • May 2022
  • Region: Global
  • Future Market Insights
  • ID: 5660127
A recent market study published on the depression treatment market offers a global industry analysis for 2012-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics.

On conducting thorough research on the historical as well as current growth parameters of the depression treatment market, growth prospects of the market are obtained with maximum precision.

The report features unique and salient factors that may make a huge impact on the development of the depression treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.

The report provides detailed information about the current and future growth prospects of the depression treatment market in the most comprehensive way for a better understanding of readers.

Key Segments of the Depression treatment Market

This study on the depression treatment market offers information divided into four important segments - products, disease, distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

By Products

  • Drugs
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Citalopram
  • Escitalopram
  • Fluoxetine
  • Fluvoxamine
  • Paroxetine
  • Sertraline
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Desvenlafaxine succinate
  • Duloxetine
  • Levomilnacipran
  • Venlafaxine
  • Bupropion
  • Mirtazapine
  • Monoamine oxidase inhibitors (MAOIs)
  • Phenelzine
  • Tranylcypromine
  • Antipsychotics
  • Lithium carbonate
  • Aripiprazole
  • Brexipiprazole
  • Quetiapine
  • Trazodone
  • Others
  • TMS Devices
  • rTMS Devices
  • dTMS Devices

By Disease

  • Major Depression
  • Persistent Depressive Disorder
  • Bipolar Disorder
  • Seasonal Affective Disorder (SAD)
  • Postpartum Depression
  • Premenstrual Dysphoric Disorder (PDD)
  • Situational Depression
  • Atypical Depression
  • Treatment-Resistant Depression

By Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • e-commerce
  • Specialty Clinics

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Chapter 01 - Executive Summary

  • The report commences with the executive summary of the depression treatment market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the depression treatment market as well as the key trends affecting the market.

Chapter 02 - Market Overview

  • Readers can find detailed taxonomy and product definition/scope /limitations, inclusions, and exclusions of the depression treatment market in this chapter, which helps readers, understand basic information about depression treatment.

Chapter 03 - Key Market Trends

  • This section highlights the key trends impacting the depression treatment market, which will help readers in understanding the current trends and their impact on market growth.

Chapter 04 - Key Success Factors

  • This section highlights the key success factors impacting the depression treatment market, which will help readers in understanding disease epidemiology by region, drug adoption/usage analysis, new drugs approvals and launches, key promotional strategies by market players, pipeline analysis, regulatory scenario, PESTLE analysis, Porter’s analysis and value chain analysis that is expected to create a positive impact on the growth of the depression treatment market during the forecast period.

Chapter 05 - Market Background

  • This chapter explains the key macroeconomic factors that are expected to influence the growth of the depression treatment market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the depression treatment market, which include the drivers, restraints, and opportunity analysis.

Chapter 06- COVID-19 Crisis Analysis

  • This section provides the current and expected impact of COVID-19 on the depression treatment market.

Chapter 07 - Global Depression Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012-2021 and Forecast, 2022-2032

  • This section explains the global market demand (in value or size in US$ Mn) analysis and forecast for the depression treatment market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2021), and an incremental $ opportunity for the forecast period (2022-2032).

Chapter 08 - Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Products

  • Based on products, the depression treatment market is segmented into drugs (selective serotonin reuptake inhibitors (SSRIs) {citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline}, selective norepinephrine reuptake inhibitors (SNRIs) {desvenlafaxine succinate, duloxetine, levomilnaipran, and venlafaxine}, bupropion, mirtazapine, monoamine oxidase inhibitors (MAOIs) {phenelzine and tranylcypromine}, antipsychotics {lithium carbonate, aripiprazole, brexipiiprazole, quetiapine}, trazodone and others) and TMS devices (rTMS devices, dTMS devices).
  • In this chapter, readers can find information about a detailed analysis of the market by different products available in the depression treatment market and their growth over the forecast period.

Chapter 09 - Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, By Disease

  • Based on disease, the depression treatment market is segmented into major depression, persistent depressive disorder, bipolar disorder, seasonal affective disorder (SAD), postpartum depression, premenstrual dysphoric disorder (PDD), situational depression, atypical depression and treatment-resistant depression.
  • In this chapter, readers can find information about a detailed analysis of the market by different diseases in the depression treatment market and their growth over the forecast period.

Chapter 10 - Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Distribution Channel

  • Based on the distribution channel, the depression treatment market is segmented into hospitals, retail pharmacies, drug stores, e-commerce, and speciality clinics. In this chapter, readers can find information about a detailed analysis of the market by different distribution channel available in the depression treatment market and their growth over the forecast period.

Chapter 11 - Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Region

  • This chapter explains how the depression treatment market will grow across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East and Africa (MEA).

Chapter 12 - North America Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • This chapter includes a detailed analysis of the growth of the North American depression treatment market along with the country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on product, disease, distribution channel, and country of the depression treatment market in the North American region.

Chapter 13 - Latin America Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • This chapter includes the growth prospects of the depression treatment market in leading countries such as Brazil, Mexico, Argentina and the rest of Latin America. Readers can find thorough information about the growth parameters based on product, disease, distribution channel, and country in the Latin America depression treatment market during 2022-2032.

Chapter 14 - Europe Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • This chapter includes the growth prospects of the depression treatment market based on the development of the new product and regulatory approvals in several European countries such as the U.K., Germany, Italy, France, Spain, Russia, BENELUX and the Rest of Europe are included in this chapter.

Chapter 15 - South Asia Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • India, Thailand, Indonesia, Malaysia, and the rest of South Asia are the prime subjects of assessment to obtain the growth prospects of the depression treatment market. In addition, in this chapter, readers can find thorough information about the growth parameters of the South Asia depression treatment market growth over the forecast period.

Chapter 16 - East Asia Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • China, Japan, and South Korea are the prime subjects of assessment to obtain the growth prospects of the East Asia depression treatment market. In addition, in this chapter, readers can find thorough information about the growth parameters of the East Asia depression treatment market through 2031.

Chapter 17 - Oceania Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • This chapter consists of important parameters that have a huge impact on the growth of the depression treatment market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania depression treatment market.

Chapter 18 - Middle East and Africa Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032

  • This chapter provides information on how the depression treatment market will grow in the major countries in the MEA region, such as Turkey, GCC Countries, South
Africa and North Africa during 2022-2032.

Chapter 19 - Market Structure Analysis

  • This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key players operating in the depression treatment market.

Chapter 20 - Competition Analysis

  • In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the depression treatment market including the company overview, revenue shares, strategic overview, and recent company developments.
  • Some of the market players featured in the report include Viatris (Mylan Pharmaceuticals Inc.), Sunovian Pharmaceuticals, AbbVie Inc. (Allergan, Inc.), Jubilant Generics Limited, Sanis Health Inc., Abbott Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals, Teva Pharmaceuticals, Sun Pharmaceuticals, (Apotex Holdings, Inc.) Apotex Corporation, Alembic Pharmaceuticals Limited, Pfizer Inc., Cardinal Health, Hikma Pharmaceuticals, Zydus Lifesciences (Cadila), Cipla Ltd, Dr. Reddy's Laboratories, Merck & Co., Eli Lily & Co, GlaxoSmithKline, Takeda Pharmaceuticals, BrainsWay Ltd., Nexstim Plc., Magstim Ltd., Neuronetics, Inc., Salience TMS Neuro Solutions, MagVenture, MAG & More GmbH and Neurosoft, Ltd.

Chapter 21 - Assumptions and Acronyms Used

  • This chapter includes a list of acronyms and assumptions that provide a base for the information and statistics included in the report.

Chapter 22 - Research Methodology

  • This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the depression treatment market.

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation/Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, By Region
4.2. Drug Adoption/Usage Analysis
4.3. New Drug Approvals & Launches
4.4. Key Promotional Strategies by Market Players
4.5. Pipeline Analysis
4.6. Regulatory Scenario
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Value Chain analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Market Outlook
5.1.3. Global Mental Health Disorders Market Outlook
5.1.4. Global Pharmaceutical Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Product Adoption Rate and Demand
5.2.3. Increasing burden of mental illnesses
5.2.4. Availability of various therapies
5.2.5. COVID-19 impact
5.2.6. Technological Advancements in Equipment
5.2.7. Increasing Demand for Depression Disorders Treatment
5.2.8. New Product Launches
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. COVID19 and Impact Analysis
6.4. 2021 Market Scenario
7. Global Depression Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2012-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Product Type
8.1. Introduction/Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2012-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2022-2032
8.3.1. Drugs
8.3.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
8.3.1.1.1. Citalopram
8.3.1.1.2. Escitalopram
8.3.1.1.3. Fluoxetine
8.3.1.1.4. Fluvoxamine
8.3.1.1.5. Paroxetine
8.3.1.1.6. Sertraline
8.3.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
8.3.1.2.1. Desvenlafaxine succinate
8.3.1.2.2. Duloxetine
8.3.1.2.3. Levomilnacipran
8.3.1.2.4. Venlafaxine
8.3.1.3. Bupropion
8.3.1.4. Mirtazapine
8.3.1.5. Monoamine oxidase inhibitors (MAOIs)
8.3.1.5.1. Phenelzine
8.3.1.5.2. Tranylcypromine
8.3.1.6. Antipsychotics
8.3.1.6.1. Lithium carbonate
8.3.1.6.2. Aripiprazole
8.3.1.6.3. Brexipiprazole
8.3.1.6.4. Quetiapine
8.3.1.7. Trazodone
8.3.1.8. Others
8.3.2. TMS Devices
8.3.2.1. rTMS Devices
8.3.2.2. dTMS Devices
8.4. Market Attractiveness Analysis By Disease Type
9. Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Disease Type
9.1. Introduction/Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032
9.3.1. Major Depression
9.3.2. Persistent Depressive Disorder
9.3.3. Bipolar Disorder
9.3.4. Seasonal Affective Disorder (SAD)
9.3.5. Postpartum Depression
9.3.6. Premenstrual Dysphoric Disorder (PDD)
9.3.7. Situational Depression
9.3.8. Atypical Depression
9.3.9. Treatment-Resistant Depression
9.4. Market Attractiveness Analysis By Disease Type
10. Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Distribution Channel
10.1. Introduction/Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel 2022-2032
10.3.1. Hospitals
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. e-commerce
10.3.5. Specialty Clinics
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis, By Region, 2012-2021
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Product Type
12.3.3. By Disease Type
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By Disease Type
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Depression Treatment Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product Type
12.8.1.2.2. By Disease Type
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Depression Treatment Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product Type
12.8.2.2.2. By Disease Type
12.8.2.2.3. By Distribution Channel
13. Latin America Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Product Type
13.3.3. By Disease Type
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By Disease Type
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Brazil Depression Treatment Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product Type
13.8.1.2.2. By Disease Type
13.8.1.2.3. By Distribution Channel
13.8.2. Mexico Depression Treatment Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product Type
13.8.2.2.2. By Disease Type
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Depression Treatment Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product Type
13.8.3.2.2. By Disease Type
13.8.3.2.3. By Distribution Channel
14. Europe Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.3.1. By Country
14.3.1.1. U.K.
14.3.1.2. Germany
14.3.1.3. Italy
14.3.1.4. France
14.3.1.5. Spain
14.3.1.6. Russia
14.3.1.7. BENELUX
14.3.1.8. Rest of Europe
14.3.2. By Product Type
14.3.3. By Disease Type
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By Disease Type
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. U.K. Depression Treatment Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product Type
14.8.1.2.2. By Disease Type
14.8.1.2.3. By Distribution Channel
14.8.2. Germany Depression Treatment Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product Type
14.8.2.2.2. By Disease Type
14.8.2.2.3. By Distribution Channel
14.8.3. Italy Depression Treatment Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product Type
14.8.3.2.2. By Disease Type
14.8.3.2.3. By Distribution Channel
14.8.4. France Depression Treatment Market
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Product Type
14.8.4.2.2. By Disease Type
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Depression Treatment Market
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Product Type
14.8.5.2.2. By Disease Type
14.8.5.2.3. By Distribution Channel
14.8.6. Russia Depression Treatment Market
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Product Type
14.8.6.2.2. By Disease Type
14.8.6.2.3. By Distribution Channel
14.8.7. BENELUX Depression Treatment Market
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Disease Type
14.8.7.2.2. By Product Type
14.8.7.2.3. By Distribution Channel
15. South Asia Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Product Type
15.3.3. By Disease Type
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By Disease Type
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. India Depression Treatment Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product Type
15.8.1.2.2. By Disease Type
15.8.1.2.3. By Distribution Channel
15.8.2. Thailand Depression Treatment Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product Type
15.8.2.2.2. By Disease Type
15.8.2.2.3. By Distribution Channel
15.8.3. Indonesia Depression Treatment Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product Type
15.8.3.2.2. By Disease Type
15.8.3.2.3. By Distribution Channel
15.8.4. Malaysia Depression Treatment Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product Type
15.8.4.2.2. By Disease Type
15.8.4.2.3. By Distribution Channel
16. East Asia Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Product Type
16.3.3. By Disease Type
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product Type
16.4.3. By Disease Type
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Depression Treatment Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product Type
16.8.1.2.2. By Disease Type
16.8.1.2.3. By Distribution Channel
16.8.2. Japan Depression Treatment Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product Type
16.8.2.2.2. By Disease Type
16.8.2.2.3. By Distribution Channel
16.8.3. South Korea Depression Treatment Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product Type
16.8.3.2.2. By Disease Type
16.8.3.2.3. By Distribution Channel
17. Oceania Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Product Type
17.3.3. By Disease Type
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product Type
17.4.3. By Disease Type
17.4.4. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Depression Treatment Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product Type
17.8.1.2.2. By Disease Type
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Depression Treatment Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product Type
17.8.2.2.2. By Disease Type
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Depression Treatment Market Analysis 2012-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2021
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
18.3.1. By Country
18.3.1.1. Turkey
18.3.1.2. GCC Countries
18.3.1.3. North Africa
18.3.1.4. South Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Product Type
18.3.3. By Disease Type
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product Type
18.4.3. By Disease Type
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Turkey Depression Treatment Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product Type
18.8.1.2.2. By Disease Type
18.8.1.2.3. By Distribution Channel
18.8.2. GCC Countries Depression Treatment Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product Type
18.8.2.2.2. By Disease Type
18.8.2.2.3. By Distribution Channel
18.8.3. North Africa Depression Treatment Market
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product Type
18.8.3.2.2. By Disease Type
18.8.3.2.3. By Distribution Channel
18.8.4. South Africa Depression Treatment Market
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Product Type
18.8.4.2.2. By Disease Type
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Technology Foot-Print, By Competition
20.3. Competition Benchmarking
20.4. Competition Deep Dive
20.4.1. Viatris (Mylan Pharmaceuticals Inc.)
20.4.1.1. Overview
20.4.1.2. Product Portfolio
20.4.1.3. Key Financials
20.4.1.4. SWOT Analysis
20.4.1.5. Sales Footprint
20.4.1.6. Strategy Overview
20.4.1.7. Key Developments
20.4.2. Sunovian Pharmaceuticals
20.4.2.1. Overview
20.4.2.2. Product Portfolio
20.4.2.3. Key Financials
20.4.2.4. SWOT Analysis
20.4.2.5. Sales Footprint
20.4.2.6. Strategy Overview
20.4.2.7. Key Developments
20.4.3. AbbVie Inc (Allergan, Inc.)
20.4.3.1. Overview
20.4.3.2. Product Portfolio
20.4.3.3. Key Financials
20.4.3.4. SWOT Analysis
20.4.3.5. Sales Footprint
20.4.3.6. Strategy Overview
20.4.3.7. Key Developments
20.4.4. Jubilant Generics Limited
20.4.4.1. Overview
20.4.4.2. Product Portfolio
20.4.4.3. Key Financials
20.4.4.4. SWOT Analysis
20.4.4.5. Sales Footprint
20.4.4.6. Strategy Overview
20.4.4.7. Key Developments
20.4.5. Sanis Health Inc
20.4.5.1. Overview
20.4.5.2. Product Portfolio
20.4.5.3. Key Financials
20.4.5.4. SWOT Analysis
20.4.5.5. Sales Footprint
20.4.5.6. Strategy Overview
20.4.5.7. Key Developments
20.4.6. Abbott Laboratories
20.4.6.1. Overview
20.4.6.2. Product Portfolio
20.4.6.3. Key Financials
20.4.6.4. SWOT Analysis
20.4.6.5. Sales Footprint
20.4.6.6. Strategy Overview
20.4.6.7. Key Developments
20.4.7. Aurobindo Pharma
20.4.7.1. Overview
20.4.7.2. Product Portfolio
20.4.7.3. Key Financials
20.4.7.4. SWOT Analysis
20.4.7.5. Sales Footprint
20.4.7.6. Strategy Overview
20.4.7.7. Key Developments
20.4.8. Torrent Pharmaceuticals
20.4.8.1. Overview
20.4.8.2. Product Portfolio
20.4.8.3. Key Financials
20.4.8.4. SWOT Analysis
20.4.8.5. Sales Footprint
20.4.8.6. Strategy Overview
20.4.8.7. Key Developments
20.4.9. Teva Pharmaceuticals
20.4.9.1. Overview
20.4.9.2. Product Portfolio
20.4.9.3. Key Financials
20.4.9.4. SWOT Analysis
20.4.9.5. Sales Footprint
20.4.9.6. Strategy Overview
20.4.9.7. Key Developments
20.4.10. Sun Pharmaceuticals
20.4.10.1. Overview
20.4.10.2. Product Portfolio
20.4.10.3. Key Financials
20.4.10.4. SWOT Analysis
20.4.10.5. Sales Footprint
20.4.10.6. Strategy Overview
20.4.10.7. Key Developments
20.4.11. (Apotex Holdings, Inc.) Apotex Corporation
20.4.11.1. Overview
20.4.11.2. Product Portfolio
20.4.11.3. Key Financials
20.4.11.4. SWOT Analysis
20.4.11.5. Sales Footprint
20.4.11.6. Strategy Overview
20.4.11.7. Key Developments
20.4.12. Alembic Pharmaceuticals Limited
20.4.12.1. Overview
20.4.12.2. Product Portfolio
20.4.12.3. Key Financials
20.4.12.4. SWOT Analysis
20.4.12.5. Sales Footprint
20.4.12.6. Strategy Overview
20.4.12.7. Key Developments
20.4.13. Pfizer Inc
20.4.13.1. Overview
20.4.13.2. Product Portfolio
20.4.13.3. Key Financials
20.4.13.4. SWOT Analysis
20.4.13.5. Sales Footprint
20.4.13.6. Strategy Overview
20.4.13.7. Key Developments
20.4.14. Cardinal Health
20.4.14.1. Overview
20.4.14.2. Product Portfolio
20.4.14.3. Key Financials
20.4.14.4. SWOT Analysis
20.4.14.5. Sales Footprint
20.4.14.6. Strategy Overview
20.4.14.7. Key Developments
20.4.15. Hikma Pharmaceuticals
20.4.15.1. Overview
20.4.15.2. Product Portfolio
20.4.15.3. Key Financials
20.4.15.4. SWOT Analysis
20.4.15.5. Sales Footprint
20.4.15.6. Strategy Overview
20.4.15.7. Key Developments
20.4.16. Zydus Lifesciences (Cadila)
20.4.16.1. Overview
20.4.16.2. Product Portfolio
20.4.16.3. Key Financials
20.4.16.4. SWOT Analysis
20.4.16.5. Sales Footprint
20.4.16.6. Strategy Overview
20.4.16.7. Key Developments
20.4.17. Cipla Ltd
20.4.17.1. Overview
20.4.17.2. Product Portfolio
20.4.17.3. Key Financials
20.4.17.4. SWOT Analysis
20.4.17.5. Sales Footprint
20.4.17.6. Strategy Overview
20.4.17.7. Key Developments
20.4.18. Dr. Reddy's Laboratories
20.4.18.1. Overview
20.4.18.2. Product Portfolio
20.4.18.3. Key Financials
20.4.18.4. SWOT Analysis
20.4.18.5. Sales Footprint
20.4.18.6. Strategy Overview
20.4.18.7. Key Developments
20.4.19. Merck & Co.
20.4.19.1. Overview
20.4.19.2. Product Portfolio
20.4.19.3. Key Financials
20.4.19.4. SWOT Analysis
20.4.19.5. Sales Footprint
20.4.19.6. Strategy Overview
20.4.19.7. Key Developments
20.4.20. Eli Lily & Co
20.4.20.1. Overview
20.4.20.2. Product Portfolio
20.4.20.3. Key Financials
20.4.20.4. SWOT Analysis
20.4.20.5. Sales Footprint
20.4.20.6. Strategy Overview
20.4.20.7. Key Developments
20.4.21. GlaxoSmithKline
20.4.21.1. Overview
20.4.21.2. Product Portfolio
20.4.21.3. Key Financials
20.4.21.4. SWOT Analysis
20.4.21.5. Sales Footprint
20.4.21.6. Strategy Overview
20.4.21.7. Key Developments
20.4.22. Takeda Pharmaceuticals
20.4.22.1. Overview
20.4.22.2. Product Portfolio
20.4.22.3. Key Financials
20.4.22.4. SWOT Analysis
20.4.22.5. Sales Footprint
20.4.22.6. Strategy Overview
20.4.22.7. Key Developments
20.4.23. BrainsWay Ltd.
20.4.23.1. Overview
20.4.23.2. Product Portfolio
20.4.23.3. Key Financials
20.4.23.4. SWOT Analysis
20.4.23.5. Sales Footprint
20.4.23.6. Strategy Overview
20.4.23.7. Key Developments
20.4.24. Nexstim Plc
20.4.24.1. Overview
20.4.24.2. Product Portfolio
20.4.24.3. Key Financials
20.4.24.4. SWOT Analysis
20.4.24.5. Sales Footprint
20.4.24.6. Strategy Overview
20.4.24.7. Key Developments
20.4.25. Magstim Ltd.
20.4.25.1. Overview
20.4.25.2. Product Portfolio
20.4.25.3. Key Financials
20.4.25.4. SWOT Analysis
20.4.25.5. Sales Footprint
20.4.25.6. Strategy Overview
20.4.25.7. Key Developments
20.4.26. Neuronetics, Inc.
20.4.26.1. Overview
20.4.26.2. Product Portfolio
20.4.26.3. Key Financials
20.4.26.4. SWOT Analysis
20.4.26.5. Sales Footprint
20.4.26.6. Strategy Overview
20.4.26.7. Key Developments
20.4.27. Salience TMS Neuro Solutions
20.4.27.1. Overview
20.4.27.2. Product Portfolio
20.4.27.3. Key Financials
20.4.27.4. SWOT Analysis
20.4.27.5. Sales Footprint
20.4.27.6. Strategy Overview
20.4.27.7. Key Developments
20.4.28. MagVenture
20.4.28.1. Overview
20.4.28.2. Product Portfolio
20.4.28.3. Key Financials
20.4.28.4. SWOT Analysis
20.4.28.5. Sales Footprint
20.4.28.6. Strategy Overview
20.4.28.7. Key Developments
20.4.29. MAG & More GmbH
20.4.29.1. Overview
20.4.29.2. Product Portfolio
20.4.29.3. Key Financials
20.4.29.4. SWOT Analysis
20.4.29.5. Sales Footprint
20.4.29.6. Strategy Overview
20.4.29.7. Key Developments
20.4.30. Neurosoft, Ltd.
20.4.30.1. Overview
20.4.30.2. Product Portfolio
20.4.30.3. Key Financials
20.4.30.4. SWOT Analysis
20.4.30.5. Sales Footprint
20.4.30.6. Strategy Overview
20.4.30.7. Key Developments
21. Assumptions and Acronyms Used22. Research Methodology

Companies Mentioned

  • Viatris (Mylan Pharmaceuticals Inc.)
  • Sunovian Pharmaceuticals
  • AbbVie Inc. (Allergan Inc.)
  • Jubilant Generics Limited
  • Sanis Health Inc.
  • Abbott Laboratories
  • Aurobindo Pharma
  • Torrent Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • (Apotex Holdings Inc.) Apotex Corporation
  • Alembic Pharmaceuticals Limited
  • Pfizer Inc.
  • Cardinal Health
  • Hikma Pharmaceuticals
  • Zydus Lifesciences (Cadila)
  • Cipla Ltd
  • Dr. Reddy's Laboratories
  • Merck & Co.
  • Eli Lily & Co
  • GlaxoSmithKline
  • Takeda Pharmaceuticals
  • BrainsWay Ltd.
  • Nexstim Plc
  • Magstim Ltd.
  • Neuronetics Inc.
  • Salience TMS Neuro Solutions
  • MagVenture
  • MAG & More GmbH
  • Neurosoft Ltd.